164 related articles for article (PubMed ID: 29027261)
1. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
Alhuraiji A; Kantarjian H; Boddu P; Ravandi F; Borthakur G; DiNardo C; Daver N; Kadia T; Pemmaraju N; Pierce S; Garcia-Manero G; Wierda W; Verstovsek S; Jabbour E; Cortes J
Am J Hematol; 2018 Jan; 93(1):84-90. PubMed ID: 29027261
[TBL] [Abstract][Full Text] [Related]
2. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
4. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
6. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
Falchi L; Kantarjian HM; Wang X; Verma D; Quintás-Cardama A; O'Brien S; Jabbour EJ; Ravandi-Kashani F; Borthakur G; Garcia-Manero G; Verstovsek S; Burger JA; Luthra R; Cortes JE
Am J Hematol; 2013 Dec; 88(12):1024-9. PubMed ID: 23913852
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
Klamová H; Poláková KM; Mužík J; Ráčil Z; Záčková D; Steinerová K; Karas M; Faber E; Demečková E; Michalovičová-Sninská Z; Voglová J; Demitrovičová L; Mikušková E; Tóthová E; Chudej J; Markuljak I; Cmunt E; Moravcová J; Dvořáková D; Michalová K; Jarošová M; Sťastná MM; Cetkovský P; Dušek L; Koza V; Trněný M; Indrák K
Cancer Med; 2013 Apr; 2(2):216-25. PubMed ID: 23634289
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon.
Massoud M; Sakr R; Kerbage F; Makdissi J; Hawi J; Rached L; Nasr F; Chahine G
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S111-S115. PubMed ID: 28760296
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
11. Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution.
Falchi L; Rege-Cambrin G; Fava C; Donti E; Luzi D; Giugliano E; Gubbiotti M; Schippa M; Liberati AM
Cancer Genet Cytogenet; 2010 Jun; 199(2):139-42. PubMed ID: 20471518
[TBL] [Abstract][Full Text] [Related]
12. [Effects of Tyrosine Kinase Inhibitors on the Th1 and Treg Cells of CML Patients].
Dai JY; Yang X; Wei Q; Li H; Huang XB; Wang XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):25-32. PubMed ID: 30738443
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
15. Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience.
Tantiworawit A; Kongjarern S; Rattarittamrong E; Lekawanvijit S; Bumroongkit K; Boonma N; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Norasetthada L
Asian Pac J Cancer Prev; 2016; 17(4):2159-64. PubMed ID: 27221912
[TBL] [Abstract][Full Text] [Related]
16. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Quintás-Cardama A; Kantarjian H; Shan J; Jabbour E; Abruzzo LV; Verstovsek S; Garcia-Manero G; O'Brien S; Cortes J
Cancer; 2011 Nov; 117(22):5085-93. PubMed ID: 21523765
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Nishiyama-Fujita Y; Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto K; Fujita H; Fujioka I; Tsuchiya S; Kimura Y; Iwanaga E; Komatsu N; Asou N; Kizaki M; Hatta Y; Kawaguchi T
Ann Med; 2022 Dec; 54(1):1244-1254. PubMed ID: 35486442
[TBL] [Abstract][Full Text] [Related]
20. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Garg RJ; Kantarjian H; O'Brien S; Quintás-Cardama A; Faderl S; Estrov Z; Cortes J
Blood; 2009 Nov; 114(20):4361-8. PubMed ID: 19729517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
